Johnson & Johnson acquires Actelion

January 26, 2017 News BioVox

After weeks of rumors, the news was finally announced this morning. J&J is to buy Europes largest biotech company for a whopping $30 billion. The R&D division of the Swiss company will be spun out as a new company listed on the Swiss stock market.

Actelion was founded 20 years ago by ex-Roche employees and focused on rare diseases. The company currently has 4 products on the market, including blockbuster Tracleer. Tracleer is used to treat pulmonary arterial hypertension and made a turnover of 1.6 billion in the first 9 months of 2016.

Read the full press release here.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter